Nilda Mesa Sells 258 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) Director Nilda Mesa sold 258 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $581.93, for a total transaction of $150,137.94. Following the transaction, the director owned 5,028 shares of the company’s stock, valued at approximately $2,925,944.04. This represents a 4.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

United Therapeutics Stock Down 0.6%

Shares of UTHR opened at $575.79 on Friday. The stock has a market cap of $24.44 billion, a price-to-earnings ratio of 21.25, a P/E/G ratio of 1.83 and a beta of 0.60. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35. The company has a 50-day moving average price of $556.50 and a two-hundred day moving average price of $506.65.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The business had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $6.63 EPS. Equities research analysts expect that United Therapeutics Corporation will post 27.64 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of UTHR. Public Employees Retirement System of Ohio raised its position in United Therapeutics by 13.6% in the 1st quarter. Public Employees Retirement System of Ohio now owns 25,010 shares of the biotechnology company’s stock worth $14,830,000 after purchasing an additional 3,003 shares during the last quarter. Atika Capital Management LLC bought a new position in United Therapeutics in the 1st quarter worth approximately $7,323,000. Bowen Hanes & Co. Inc. bought a new position in United Therapeutics in the 1st quarter worth approximately $50,403,000. Sei Investments Co. raised its position in United Therapeutics by 5.9% in the 1st quarter. Sei Investments Co. now owns 28,421 shares of the biotechnology company’s stock worth $16,853,000 after purchasing an additional 1,589 shares during the last quarter. Finally, Lido Advisors LLC raised its position in United Therapeutics by 156.7% in the 1st quarter. Lido Advisors LLC now owns 1,653 shares of the biotechnology company’s stock worth $981,000 after purchasing an additional 1,009 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on UTHR shares. Oppenheimer lifted their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Morgan Stanley set a $516.00 target price on shares of United Therapeutics in a research note on Thursday, May 7th. Raymond James Financial started coverage on shares of United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price for the company. Finally, Royal Bank Of Canada cut their target price on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.